Cantor Fitzgerald Reiterates Overweight on Harmony Biosciences, Maintains $49 Price Target

Harmony Biosciences Holdings +2.04% Post

Harmony Biosciences Holdings

HRMY

29.95

29.95

+2.04%

0.00% Post

Cantor Fitzgerald analyst Charles Duncan reiterates Harmony Biosciences (NASDAQ: HRMY) with a Overweight and maintains $49 price target.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via